ACTI is a new and unique business incubator providing access to the China healthcare market.
The program is open to Australian companies in the MedTech and life sciences sector and is supported by a team with significant experience in start-up and business mentoring in Australia and China, including registering, launching and marketing medical devices, IVDs and innovation led products in both markets.
ACTI’s incubation program is jointly delivered in Australia and China. During the first phase, the Shanghai-based mentoring and investment team will provide intensive training and mentoring programs in Australia, equipping companies with a tailor-made China entry strategy and business plan.
Companies identified as being ‘China Ready’ will progress to ACTI’s dedicated business incubation space in Shanghai, where they will be co-located with Chinese high-tech companies and supported by a highly experienced business incubation team that is currently assisting more than 100 companies.
All qualifying Australian companies will be given the opportunity to apply for funds from ACTI’s proprietary angel investment fund in Shanghai, established to provide funds to expand into the Chinese market.
Until the Shanghai Masterclass Bootcamp
China’s Healthcare Opportunity
Already worth more than $500 billion, China is the world’s second largest healthcare market, estimated to reach $1 trillion by 2020.
More than 3 million people in China contract or die from cancer each year.
400 million Chinese suffer from hypertension, 100 million have diabetes (500 million are considered pre-diabetics).
China’s 65+ population already numbers more than 200 million and is projected to exceed 500 million by 2050.
ACTI is supported by funding from the Australian Government under its Entrepreneurs’ Programme.
49 Agnes Street
0411 679 888